Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biomea Fusion, Inc.

NASDAQ: BMEA · Life Sciences · 4 alerts · CIK 1840439

Share price
$0.5201Close, Nov 16
Market cap
$37.8M
Shares outstanding
72.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biomea Fusion, Inc. filings on SEC EDGAR ↗

6:00 AM ET 8-K
Clinical Trial Data

Biomea Fusion Clinical Trial Data

Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.

4:02 PM ET 8-K
Clinical Trial Data

Biomea Fusion Clinical Trial Data

Biomea Fusion updated the anticipated timing for topline results from its Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The company now expects to release the data in October 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.